Blueberry Therapeutics have unique nanopolymer drug delivery technology... ...which opens up huge opportunities to rapidly develop new medicines... ...and helps us find ways to treat dermatological disorders.
Blueberry CEO John Ridden has been invited to speak at BioCap this October at Alderley Park. John is pleased to [...]
Susan Yau2019-09-25T09:25:50+00:00September 25th, 2019|
A Blueberry case study
In this video, CEO John Ridden and CSO David Cook talk about the early days of Blueberry Therapeutics, the short term and long term plans for the company, and the benefits of being based at Alderley Park, Cheshire.